PRACTICAL ASPECTS OF APIXABAN USE IN CLINICAL PRACTICE: VIEW POINT OF CLINICAL PHARMACOLOGIST
Рациональная фармакотерапия в кардиологии, 2015 Apixaban is a "new" oral anticoagulant, direct Xa factor inhibitor with a good evidence base of the efficacy in the prevention of ischemic stroke in patients with atrial fibrillation.
D. A. Sychev +6 more
doaj +3 more sources
Apixaban vs. Warfarin in Atrial Fibrillation Patients With Chronic Kidney Disease
Frontiers in Cardiovascular Medicine, 2021 Background and Objectives: Real-world evidence of apixaban treatment in patients with chronic kidney disease remains scarce. This study aimed to compare the relative risk of stroke or systemic embolism (SE) and major bleeding between apixaban and ...
Chung-Ming Fu +6 more
doaj +1 more source
A study on indices of apixaban anticoagulation: A single-center prospective study
Journal of Pharmacological Sciences, 2018 Background: Depending on the characteristics of patients, the blood concentration of apixaban can unexpectedly increase, possibly leading to bleeding events.
Maki Komiyama +11 more
doaj +1 more source
Eficacia de los Anticoagulantes Orales Directos (DOAC) en la terapia antitrombótica para pacientes con fibrilación auricular no valvular. [PDF]
, 2023 The objective of this study is to analyze the characteristics of direct oral anticoagulants (DOACs) and determine which of them is the most appropriate according to the clinical characteristics of each patient.
Jurado Carrera, Pablo Danilo +2 more
core +2 more sources
Dabigatrán su eficacia y seguridad en el tratamiento de la fibrilación auricular de origen no valvular. Experiencia personal de tres años [PDF]
, 2014 La fibrilación auricular (FA) es la arritmia cardiaca sostenida más frecuente con una prevalencia en la población general del 1.5 al 2%1 que aumenta con la edad llegando hasta el 15% en la población igual o mayor a los 80 años2 .
Muñoz Rogel, M., Salgado, M.
core +1 more source
Critical Analysis of Apixaban Dose Adjustment Criteria
Clinical and Applied Thrombosis/Hemostasis, 2021 Apixaban is indicated for the prevention of ischemic stroke in non-valvular atrial fibrillation (NVAF), as well as for the prevention and treatment of venous thromboembolism (VTE).
Anh Vu PharmD +5 more
doaj +1 more source
Frontiers in Pharmacology, 2022 Introduction: Accumulation of apixaban in plasma is a major concern in patients with chronic kidney disease (CKD). Studies that investigated plasma apixaban level in CKD patients and its association with clinically significant events are scarce.Methods ...
Chun-fung Sin +5 more
doaj +1 more source
Uso de nuevos anticoagulantes orales (NACO) en la prevención del ictus y la embolia sistémica en pacientes con fibrilación auricular no valvular (FANV) [PDF]
, 2018 Introducción: Las herramientas de ayuda para la toma de decisiones compartidas son materiales, con información fiable basada en estudios científicos, sobre una determinada enfermedad o problema de salud en cuestión.
Lizán, Luis +4 more
core +2 more sources
CPT: Pharmacometrics & Systems Pharmacology, 2023 This study aimed to characterize apixaban pharmacokinetics (PKs) and its variability in a real‐world clinical setting of hospitalized patients using a population PK (PopPK) approach. Model‐based simulations helped to identify factors that affect apixaban
Frédéric Gaspar +11 more
doaj +1 more source
Apixaban as a Rare Cause of Leukocytoclastic Vasculitis
Case Reports in Rheumatology, 2020 Apixaban is a rare cause of leukocytoclastic vasculitis (LCV). To our knowledge, there is only one other reported case due to apixaban in the literature. We present a case of apixaban-induced leukocytoclastic vasculitis in a 95-year-old male. He had been
Jenna Spears +4 more
doaj +1 more source